JP2007522447A - 細胞傷害性アッセイ - Google Patents

細胞傷害性アッセイ Download PDF

Info

Publication number
JP2007522447A
JP2007522447A JP2006551314A JP2006551314A JP2007522447A JP 2007522447 A JP2007522447 A JP 2007522447A JP 2006551314 A JP2006551314 A JP 2006551314A JP 2006551314 A JP2006551314 A JP 2006551314A JP 2007522447 A JP2007522447 A JP 2007522447A
Authority
JP
Japan
Prior art keywords
cells
caspase
assay
peptide
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2006551314A
Other languages
English (en)
Japanese (ja)
Inventor
ダン，パメラ
ハー，リーウェイ
ラドヴァンイ，ラスツロ
サラ，ダニエレ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of JP2007522447A publication Critical patent/JP2007522447A/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2006551314A 2004-01-23 2005-01-21 細胞傷害性アッセイ Abandoned JP2007522447A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53899304P 2004-01-23 2004-01-23
PCT/US2005/001993 WO2005090990A2 (en) 2004-01-23 2005-01-21 Cytotoxicity assay

Publications (1)

Publication Number Publication Date
JP2007522447A true JP2007522447A (ja) 2007-08-09

Family

ID=34966212

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006551314A Abandoned JP2007522447A (ja) 2004-01-23 2005-01-21 細胞傷害性アッセイ

Country Status (11)

Country Link
EP (1) EP1706744A2 (zh)
JP (1) JP2007522447A (zh)
KR (1) KR20070001930A (zh)
CN (1) CN101065669A (zh)
AU (1) AU2005224597A1 (zh)
BR (1) BRPI0506488A (zh)
CA (1) CA2559394A1 (zh)
IL (1) IL176938A0 (zh)
MX (1) MXPA06008336A (zh)
WO (1) WO2005090990A2 (zh)
ZA (1) ZA200605715B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016129335A1 (ja) * 2015-02-09 2016-08-18 株式会社ライフアートビレッジ 免疫細胞療法のためのペプチドスクリーニング方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013126720A2 (en) * 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing
US10568947B2 (en) 2014-07-21 2020-02-25 Novartis Ag Treatment of cancer using a CLL-1 chimeric antigen receptor
SG11201700476VA (en) 2014-07-21 2017-02-27 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
CN105547971B (zh) * 2016-01-08 2018-05-01 首都医科大学附属北京友谊医院 细胞毒性t细胞脱颗粒的流式细胞术检测方法
CN105445171B (zh) * 2016-01-08 2018-03-02 首都医科大学附属北京友谊医院 自然杀伤细胞脱颗粒的流式细胞术检测方法
US11608382B2 (en) 2018-06-13 2023-03-21 Novartis Ag BCMA chimeric antigen receptors and uses thereof
CN118401673A (zh) * 2021-12-06 2024-07-26 上海药明生物技术有限公司 用于测量抗体依赖性细胞介导的细胞毒性的3d生物测定

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211548A1 (en) * 2002-01-29 2003-11-13 Oncolmmunin, Inc. Visualization and quantitiation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers
US20070154464A1 (en) * 2003-11-14 2007-07-05 Jerome Keith R Methods for screening for agents capable of modulating t lymphocyte function in response to a herpes simplex virus-infected cell

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016129335A1 (ja) * 2015-02-09 2016-08-18 株式会社ライフアートビレッジ 免疫細胞療法のためのペプチドスクリーニング方法
JPWO2016129335A1 (ja) * 2015-02-09 2017-12-14 株式会社ライフアートビレッジ 免疫細胞療法のためのペプチドスクリーニング方法

Also Published As

Publication number Publication date
CA2559394A1 (en) 2005-09-29
AU2005224597A1 (en) 2005-09-29
WO2005090990A3 (en) 2007-01-11
KR20070001930A (ko) 2007-01-04
IL176938A0 (en) 2006-12-10
WO2005090990A2 (en) 2005-09-29
ZA200605715B (en) 2007-04-25
MXPA06008336A (es) 2007-04-17
BRPI0506488A (pt) 2007-02-13
CN101065669A (zh) 2007-10-31
EP1706744A2 (en) 2006-10-04

Similar Documents

Publication Publication Date Title
Tsuji et al. Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial
Engelhard et al. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma
Keilholz et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy
Clay et al. Assays for monitoring cellular immune responses to active immunotherapy of cancer
CN107106612B (zh) 选择用于过继细胞疗法的t细胞系及其供体的方法
JP2007522447A (ja) 細胞傷害性アッセイ
Kleihauer et al. Ex vivo generation of human cytomegalovirus‐specific cytotoxic T cells by peptide‐pulsed dendritic cells
Speiser et al. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity
Yee et al. Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses
Yee et al. In vivo tracking of tumor-specific T cells
US20190030150A1 (en) Cancer Therapy
WO2014098012A1 (ja) ヘルパーt細胞の活性化方法
US20230184748A1 (en) Measuring frequency of pathogen-specific t cells in peripheral blood
Matko et al. PRAME peptide‐specific CD8+ T cells represent the predominant response against leukemia‐associated antigens in healthy individuals
Davis et al. A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant
Chamakh-Ayari et al. Leishmania major large RAB GTPase is highly immunogenic in individuals immune to cutaneous and visceral leishmaniasis
DeVette et al. A pipeline for identification and validation of tumor-specific antigens in a mouse model of metastatic breast cancer
CA2614893A1 (en) Stable quantitation and detection of immune response levels with non-zero background peptides
ES2642184T3 (es) Péptidos para su uso en el tratamiento y diagnóstico de cánceres positivos a IDH1 R132H
Disis et al. Clinical translation of peptide-based vaccine trials: the HER-2/neu model
de Beukelaar et al. No evidence for circulating HuD-specific CD8+ T cells in patients with paraneoplastic neurological syndromes and Hu antibodies
Provenzano et al. The matrix protein pp65341‐350: a peptide that induces ex vivo stimulation and in vitro expansion of CMV‐specific CD8+ T cells in subjects bearing either HLA‐A* 2402 or A* 0101 allele
Tenma et al. AJP001, a novel helper T‐cell epitope, induces a humoral immune response with activation of innate immunity when included in a peptide vaccine
CN113167786A (zh) 免疫细胞的分析方法及细胞分析装置
Nguyen-Hoai et al. Gene gun Her2/neu DNA vaccination: evaluation of vaccine efficacy in a syngeneic Her2/neu mouse tumor model

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071012

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20081010